PMA device
Edwards Alterra Adaptive Prestent System
Edwards Lifesciences, LLC · Pulmonary Valve Prosthesis Percutaneously Delivered (NPV, ) · First FDA decision Aug 8, 2022, newest Aug 8, 2022Congenital heart disease
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
1
PMA pathway
Device trials
2
Naming "Alterra Adaptive Prestent"
MAUDE reports
128
Brand "Alterra Adaptive Prestent", since 2015
PubMed studies
13
Mentioning "Alterra Adaptive Prestent"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Edwards Alterra Adaptive Prestent System
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 1 of 1 decisions filed under this name.
- Edwards Alterra Adaptive Prestent SystemPMA supplement
P200015-S020 · Decided Aug 8, 2022 · 105 days after receipt · Normal 180 Day Track No User Fee
Device type: Pulmonary valve prosthesis percutaneously delivered (NPV) · Cardiology
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "Alterra Adaptive Prestent", any status and sponsor, newest update first.
- ALTERRA: SAPIEN 3 THV With the Alterra Adaptive PrestentActive, not recruiting
Edwards LifesciencesPublic (EW)
NCT03130777 · 86 participants · Start Aug 22, 2017 · Primary completion Jul 14, 2022
Device: Edwards Alterra Adaptive Prestent with SAPIEN 3 THV · For: Pulmonary Disease; Transcatheter Pulmonary Valve Replacement (TPVR); Tetralogy of Fallot and 2 more
Sites: Los Angeles, California; San Francisco, California; Aurora, Colorado · 14 sites in all
- ALTERRA Post-Approval StudyActive, not recruiting
Edwards LifesciencesPublic (EW)
NCT05378386 · 150 participants · Start May 12, 2022 · Primary completion Sep 25, 2025
Device: Edwards Alterra Adaptive Prestent with SAPIEN 3 Transcatheter Pulmonary Valve System · For: Pulmonary Valve Insufficiency; Complex Congenital Heart Defect; Tetralogy of Fallot and 2 more
Sites: Birmingham, Alabama; Little Rock, Arkansas; Los Angeles, California · 24 sites in all
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Alterra Adaptive Prestent", and for the whole product code for context.
This brand
128 reports: 67 malfunction, 59 injury, 2 death
Whole product code NPV
2,196 reports: 375 malfunction, 1,749 injury, 72 death
Newest reports for this brand
2015691-2026-19381 · Received Oct 14, 2026 · Event dated Jun 9, 2026
Device type: Pulmonary Valve Prosthesis Percutaneously Delivered (NPV)
Device problem as coded: Migration
Patient problem as coded: Insufficient Information
2015691-2026-18875 · Received Sep 25, 2026
Device type: Pulmonary Valve Prosthesis Percutaneously Delivered (NPV)
Device problem as coded: Insufficient Device Problem Information
Patient problem as coded: Insufficient Information
2015691-2026-18809 · Received Sep 23, 2026 · Event dated Aug 27, 2026
Device type: Pulmonary Valve Prosthesis Percutaneously Delivered (NPV)
Device problem as coded: Fluid/Blood Leak
Patient problem as coded: Dyspnea
2 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "Alterra Adaptive Prestent"[tiab]. The summary above synthesizes these.
- Multicenter Pivotal Study of the Alterra Adaptive Prestent for the Treatment of Pulmonary Regurgitation.
Dimas VV, Babaliaros V, Kim D, et al. · JACC Cardiovasc Interv · 2024Multicenter Study, Clinical Trial
- Alterra Adaptive Prestent and SAPIEN 3 THV for Congenital Pulmonic Valve Dysfunction: An Early Feasibility Study.
Shahanavaz S, Balzer D, Babaliaros V, et al. · JACC Cardiovasc Interv · 2020Research Support, Non-U.S. Gov't
- Extravascular protrusion of the Alterra adaptive prestent identified on surveillance computed tomography imaging.
Gillespie MJ, Maschietto N, Aboulhosn JA, et al. · Catheter Cardiovasc Interv · 2024Case Reports
- Alterra adaptive prestent system implanted via transjugular approach.
Rebonato M, Pilati M, Piccinelli E, et al. · Cardiol Young · 2025Case Reports
- Percutaneous Pulmonary Valve Implantation.
Giugno L, Faccini A, Carminati M · Korean Circ J · 2020Review
- Transcatheter Pulmonary Valve Implantation With the Alterra Adaptive Prestent and SAPIEN 3 Transcatheter Heart Valve: 3-Year Pooled Outcomes of the ALTERRA Trials.
Torres AJ, Dimas VV, Shahanavaz S, et al. · Circ Cardiovasc Interv · 2026Controlled Clinical Trial, Multicenter Study
- Ventricular Arrhythmias After Self-Expanding Transcatheter Pulmonary Valve Replacement: A Report From the SERVE Registry.
Armstrong AK, Goldstein BH, Aboulhosn J, et al. · JACC Clin Electrophysiol · 2026Multicenter Study, Research Support, Non-U.S. Gov't
- Off-Label Placement of a 26-mm SAPIEN S3 into an Alterra Adaptive Prestent to Avoid Coronary Compression.
Srivastava NS, Lozier JS, Bocks ML · J Soc Cardiovasc Angiogr Interv · 2025Case Reports
- Transcatheter Pulmonary Valve Implantation in Congenital Heart Diseases: Current Advances and Future Prospectives.
Giordano M, Marzullo R, Gaio G, et al. · Children (Basel) · 2025Review
- First human implant of the Alterra Adaptive PrestentTM : A new self-expanding device designed to remodel the right ventricular outflow tract.
Zahn EM, Chang JC, Armer D, et al. · Catheter Cardiovasc Interv · 2018Case Reports
- Complications From Transcatheter Pulmonary Valve Replacement With Self-Expanding Prestent.
Ligon RA, Nageotte SJ, Kheiwa A, et al. · JACC Case Rep · 2025Case Reports
- Single-Centre Case Series Assessment of Early Exercise Capacity Data Among Patients Who Received an Alterra Prestent and SAPIEN 3 Valve Placement.
Orr WB, Colombo JN, Roberts B, et al. · CJC Pediatr Congenit Heart Dis · 2022
Other devices of this type
Also filed under product code NPV.
- SAPIEN 3 Transcatheter Pulmonary Valve System with Alterra C Adaptive PrestentEdwards Lifesciences, LLC · PMA 2026
- Harmony TPV SystemMedtronic, Inc. · PMA 2026
- Edwards Commander Delivery SystemEdwards Lifesciences, LLC · PMA 2023
- Melody Transcatheter Pulmonary ValveMedtronic, Inc. · PMA 2017
- Harmony Transcatheter Pulmonary ValveMedtronic, Inc. · PMA 2022
- 9600CR CrimperEdwards Lifesciences, LLC · PMA 2022
- Melody TPV SystemMedtronic, Inc. · PMA 2019
- Ensemble II Transcatheter Valve Delivery SystemMedtronic, Inc. · PMA 2016
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.